Methods: This study was a cross-sectional, experimental, and analytical investigation conducted from August 2023 to March 2024. Serum IL-8 levels were quantified in patients and healthy controls using ELISA. The antibiotic susceptibility of K. pneumoniae isolates was assessed according to CLSI guidelines, and ESBL activity was determined by the nitrocefin hydrolysis test. Biofilm formation was quantified using the crystal violet assay, with and without ellagic acid treatment. In silico docking studies were conducted using AutoDock Vina to predict interactions between ellagic acid and the CTX-M-15 β-lactamase, Wza, FabH, and SdiA proteins.

Results: IL-8 levels were significantly higher in patients (223.8 ± 43.5 pg/mL) compared with controls (47.9 ± 17.3 pg/mL; p < 0.0001). All isolates were resistant to ampicillin and showed broad resistance to other antibiotics. Ellagic acid significantly reduced biofilm biomass (p = 0.0002) but concurrently increased ESBL activity (p = 0.0001). Docking demonstrated that ellagic acid was strongly bound to CTX-M-15 (-8.3 kcal/mol), had moderate interactions with Wza and SdiA, whereas the interaction with FabH was relatively low.

Discussion: The high concentration of IL-8 supports its use as a biomarker to detect K. pneumoniae infections. The elevated resistance profile of K. pneumoniae to antibiotics highlights the urgent need for alternative treatment approaches. Though ellagic acid increased ESBL activity, it showed distinct antibiofilm activity and responses with virulence-related proteins, indicating a modulatory action that may reduce bacterial pathogenicity. Limitations include the lack of in vivo validation and the need to mechanistically elucidate the modulation of ESBL.

Conclusion: IL-8 is a valuable biomarker for ESBL-producing K. pneumoniae infection. Ellagic acid reduces biofilm formation and targets bacterial resistance and virulence proteins, supporting its potential as a natural anti-virulence agent against multidrug-resistant K. pneumoniae.

Method: An in-depth literature search was conducted across various scientific databases, including PubMed, ClinicalTrials.gov, Scopus, and Web of Science, using relevant keywords. Both research studies and relevant data from clinical trials were thoroughly analyzed to provide a comprehensive overview of the field.

Results: The analysis indicated that immunotherapy, when used as an adjunct to established chemotherapy regimens, is more effective than when used as a standalone treatment. Immunotherapeutics enhance the body’s defenses against malignant cells, while chemotherapy directly targets rapidly dividing cancer cells. Moreover, interesting recent findings have suggested that certain chemotherapy agents at low doses selectively inhibit regulatory and suppressor cells, thereby enhancing the body’s immune response against cancer cells.

Discussion: The findings further underscore the potential synergy between chemotherapy and immunotherapy. This review delves into the concept of integrating chemotherapy and radiotherapy, which induces cell death, with immunotherapy. Specifically, emphasis is placed on ongoing clinical trials investigating immunotherapeutics in combination with chemotherapeutic agents, offering a glimpse into the future landscape of cancer treatment.

Conclusion: Immuno-chemotherapeutic combinations offer an immense opportunity, as demonstrated by numerous clinical trials. In the future, a deeper understanding of their interactions and mechanisms, identifying the optimal combination, and careful assessment of clinical responses are key to successful product development.